[{"id":"4827359c-749f-4084-aeb0-6c8f0ce2d993","acronym":"dendritic cell","url":"https://clinicaltrials.gov/study/NCT07479667","created_at":"2026-03-28T01:39:16.862Z","updated_at":"2026-03-28T01:39:16.862Z","phase":"Phase 1","brief_title":"An Antibody-armored Dendritic Cell in Patients With Solid Tumors","source_id_and_acronym":"NCT07479667 - dendritic cell","lead_sponsor":"Shanghai Cell Therapy Group Co.,Ltd","biomarkers":" KRAS • TP53","pipe":"","alterations":" ","tags":["KRAS • TP53"],"overall_status":"Recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 02/05/2026","start_date":" 02/05/2026","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 06/30/2029","study_completion_date":" 06/30/2029","last_update_posted":"2026-03-18"},{"id":"6b182771-9a0c-4d57-8725-a281a3c3973e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07474168","created_at":"2026-03-28T01:42:35.307Z","updated_at":"2026-03-28T01:42:35.307Z","phase":"Phase 1","brief_title":"T Cell Receptor Gene-Engineered and Dominant Negative TGF-β Receptor T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor","source_id_and_acronym":"NCT07474168","lead_sponsor":"Zhejiang University","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 12/15/2025","start_date":" 12/15/2025","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2032","study_completion_date":" 02/01/2032","last_update_posted":"2026-03-16"},{"id":"ce020719-ee60-4c78-aac1-c9da91de0268","acronym":"GIVEN","url":"https://clinicaltrials.gov/study/NCT07472478","created_at":"2026-03-28T01:39:49.899Z","updated_at":"2026-03-28T01:39:49.899Z","phase":"Phase 2","brief_title":"Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)","source_id_and_acronym":"NCT07472478 - GIVEN","lead_sponsor":"Guangdong Provincial People's Hospital","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • Anfangning (garsorasib) • Yidafan (ivonescimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 03/15/2026","start_date":" 03/15/2026","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 03/31/2028","study_completion_date":" 03/31/2028","last_update_posted":"2026-03-16"},{"id":"5f6c2565-8588-4402-a34b-b3e63f38e1fa","acronym":"KANDLELIT-014","url":"https://clinicaltrials.gov/study/NCT07209111","created_at":"2025-10-11T01:29:13.435Z","updated_at":"2025-10-11T01:29:13.435Z","phase":"Phase 2","brief_title":"A Clinical Study of MK-1084 in People With Advanced Solid Tumors (MK-1084-014)","source_id_and_acronym":"NCT07209111 - KANDLELIT-014","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • calderasib (MK-1084)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 11/24/2025","start_date":" 11/24/2025","primary_txt":" Primary completion: 04/09/2032","primary_completion_date":" 04/09/2032","study_txt":" Completion: 04/09/2032","study_completion_date":" 04/09/2032","last_update_posted":"2025-10-06"},{"id":"b3aaeb0c-f80e-4dde-8c61-c9b49da33a02","acronym":"","url":"https://clinicaltrials.gov/study/NCT07207707","created_at":"2025-10-11T01:26:49.129Z","updated_at":"2025-10-11T01:26:49.129Z","phase":"Phase 1","brief_title":"A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies","source_id_and_acronym":"NCT07207707","lead_sponsor":"Kumquat Biosciences Inc.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"],"overall_status":"Recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 09/16/2025","start_date":" 09/16/2025","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2025-10-06"},{"id":"7bf97edf-e25d-4101-b19d-5329b59d36b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT07204340","created_at":"2025-10-04T08:02:21.190Z","updated_at":"2025-10-04T08:02:21.190Z","phase":"Phase 1","brief_title":"TLN-372 in Advanced KRAS Mutant Solid Tumors","source_id_and_acronym":"NCT07204340","lead_sponsor":"Treeline Biosciences, Inc.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab)"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 10/09/2025","start_date":" 10/09/2025","primary_txt":" Primary completion: 12/03/2031","primary_completion_date":" 12/03/2031","study_txt":" Completion: 04/01/2032","study_completion_date":" 04/01/2032","last_update_posted":"2025-10-02"},{"id":"bedbd783-08c6-45af-8549-e837e9ef10ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT07198620","created_at":"2025-10-04T08:02:50.601Z","updated_at":"2025-10-04T08:02:50.601Z","phase":"","brief_title":"A Real-World Study of IBI351 for KRAS G12C+ NSCLC in China","source_id_and_acronym":"NCT07198620","lead_sponsor":"Guangdong Association of Clinical Trials","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Dupert (fulzerasib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 10/01/2025","start_date":" 10/01/2025","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-09-30"},{"id":"b11c3dd5-a7d2-45b9-88bd-188586703589","acronym":"","url":"https://clinicaltrials.gov/study/NCT07190248","created_at":"2025-09-27T08:39:58.068Z","updated_at":"2025-09-27T08:39:58.068Z","phase":"Phase 3","brief_title":"A Clinical Study of MK-1084 and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)","source_id_and_acronym":"NCT07190248","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1 • KRAS","pipe":"","alterations":" ","tags":["PD-L1 • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • calderasib (MK-1084)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 675","initiation":"Initiation: 10/27/2025","start_date":" 10/27/2025","primary_txt":" Primary completion: 12/07/2029","primary_completion_date":" 12/07/2029","study_txt":" Completion: 08/06/2032","study_completion_date":" 08/06/2032","last_update_posted":"2025-09-24"},{"id":"7ee22b9c-eea6-45ba-bdc2-0adfd9a6a3e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT07174908","created_at":"2025-09-20T07:06:19.138Z","updated_at":"2025-09-20T07:06:19.138Z","phase":"Phase 3","brief_title":"A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation","source_id_and_acronym":"NCT07174908","lead_sponsor":"InxMed (Shanghai) Co., Ltd.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • pemetrexed • Anfangning (garsorasib) • ifebemtinib (IN10018)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 09/01/2030","study_completion_date":" 09/01/2030","last_update_posted":"2025-09-16"},{"id":"25644c79-5dff-4f90-909f-44d8053dcbb7","acronym":"","url":"https://clinicaltrials.gov/study/NCT07148128","created_at":"2025-08-30T13:47:31.239Z","updated_at":"2025-08-30T13:47:31.239Z","phase":"Phase 1/2","brief_title":"Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.","source_id_and_acronym":"NCT07148128","lead_sponsor":"Auricula Biosciences Inc.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 07/28/2025","start_date":" 07/28/2025","primary_txt":" Primary completion: 01/01/2028","primary_completion_date":" 01/01/2028","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2025-08-29"},{"id":"ba5888d1-005c-4143-b0d5-8a1f5598d73e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07134998","created_at":"2025-08-23T13:28:10.395Z","updated_at":"2025-08-23T13:28:10.395Z","phase":"Phase 1","brief_title":"Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations","source_id_and_acronym":"NCT07134998","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 05/01/2028","primary_completion_date":" 05/01/2028","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2025-08-21"},{"id":"769c2f13-1a5f-40f3-a679-550e492e7f3c","acronym":"NeoART-M","url":"https://clinicaltrials.gov/study/NCT07095309","created_at":"2025-08-02T14:02:03.314Z","updated_at":"2025-08-02T14:02:03.314Z","phase":"Phase 2","brief_title":"Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/ III Colorectal Cancer","source_id_and_acronym":"NCT07095309 - NeoART-M","lead_sponsor":"Metanoic Health Ltd.","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 08/15/2025","start_date":" 08/15/2025","primary_txt":" Primary completion: 08/30/2032","primary_completion_date":" 08/30/2032","study_txt":" Completion: 07/31/2033","study_completion_date":" 07/31/2033","last_update_posted":"2025-07-31"},{"id":"70cc1b41-3bca-4660-a674-24287764e8ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT07094204","created_at":"2025-08-02T14:04:37.665Z","updated_at":"2025-08-02T14:04:37.665Z","phase":"Phase 1","brief_title":"A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors","source_id_and_acronym":"NCT07094204","lead_sponsor":"Astellas Pharma Inc","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vectibix (panitumumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 364","initiation":"Initiation: 07/31/2025","start_date":" 07/31/2025","primary_txt":" Primary completion: 11/30/2028","primary_completion_date":" 11/30/2028","study_txt":" Completion: 04/30/2029","study_completion_date":" 04/30/2029","last_update_posted":"2025-07-30"},{"id":"a24dd70d-457e-4bf3-b1b4-2106aa67a692","acronym":"","url":"https://clinicaltrials.gov/study/NCT07064018","created_at":"2025-07-19T14:18:32.626Z","updated_at":"2025-07-19T14:18:32.626Z","phase":"Phase 1/2","brief_title":"Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies","source_id_and_acronym":"NCT07064018","lead_sponsor":"University of California, Irvine","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Neulasta (pegfilgrastim) • Neupogen (filgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 04/30/2025","start_date":" 04/30/2025","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/31/2031","study_completion_date":" 12/31/2031","last_update_posted":"2025-07-14"},{"id":"0e00e05b-2578-4acd-967c-8c5eb860f4a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT07026916","created_at":"2025-06-21T13:17:33.061Z","updated_at":"2025-06-21T13:17:33.061Z","phase":"Phase 2","brief_title":"A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer","source_id_and_acronym":"NCT07026916","lead_sponsor":"Genfleet Therapeutics (Shanghai) Inc.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 83","initiation":"Initiation: 08/01/2025","start_date":" 08/01/2025","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2025-06-18"},{"id":"e074f097-962e-4e29-aceb-695c6e0a911d","acronym":"","url":"https://clinicaltrials.gov/study/NCT07023731","created_at":"2025-06-21T13:19:20.282Z","updated_at":"2025-06-21T13:19:20.282Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation","source_id_and_acronym":"NCT07023731","lead_sponsor":"Arvinas Inc.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"],"overall_status":"Recruiting","enrollment":" Enrollment 159","initiation":"Initiation: 05/29/2025","start_date":" 05/29/2025","primary_txt":" Primary completion: 11/30/2027","primary_completion_date":" 11/30/2027","study_txt":" Completion: 04/02/2029","study_completion_date":" 04/02/2029","last_update_posted":"2025-06-17"},{"id":"b0c3d0f3-340f-42f7-821e-d51795e6563a","acronym":"","url":"https://clinicaltrials.gov/study/NCT07020221","created_at":"2025-06-14T13:52:20.544Z","updated_at":"2025-06-14T13:52:20.544Z","phase":"Phase 1/2","brief_title":"A Phase 1/2a Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors","source_id_and_acronym":"NCT07020221","lead_sponsor":"Verastem, Inc.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2025-06-13"},{"id":"9fb2cdde-012a-4d53-b589-d932fba3f768","acronym":"C2025-009-01","url":"https://clinicaltrials.gov/study/NCT07014878","created_at":"2025-06-14T13:55:09.580Z","updated_at":"2025-06-14T13:55:09.580Z","phase":"Phase 1","brief_title":"A Study of DCTY1102 Injection in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT07014878 - C2025-009-01","lead_sponsor":"Beijing DCTY Biotech Co.,Ltd.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 05/01/2028","primary_completion_date":" 05/01/2028","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2025-06-11"},{"id":"eebefa81-1645-4e61-b40b-7636aef12cd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT07012031","created_at":"2025-06-14T13:57:15.769Z","updated_at":"2025-06-14T13:57:15.769Z","phase":"Phase 1/2","brief_title":"Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation","source_id_and_acronym":"NCT07012031","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • ERBB3","pipe":" | ","alterations":" HER-2 overexpression","tags":["KRAS • ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki) • Lumakras (sotorasib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 06/06/2025","start_date":" 06/06/2025","primary_txt":" Primary completion: 06/14/2027","primary_completion_date":" 06/14/2027","study_txt":" Completion: 06/14/2027","study_completion_date":" 06/14/2027","last_update_posted":"2025-06-11"},{"id":"c6f24729-d5a7-4244-ad7f-a2cffb7113b4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06917079","created_at":"2025-06-07T14:12:37.863Z","updated_at":"2025-06-07T14:12:37.863Z","phase":"Phase 1","brief_title":"BBO-11818 in Adult Subjects With KRAS Mutant Cancer","source_id_and_acronym":"NCT06917079","lead_sponsor":"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 287","initiation":"Initiation: 03/31/2025","start_date":" 03/31/2025","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 09/01/2029","study_completion_date":" 09/01/2029","last_update_posted":"2025-06-06"},{"id":"ff1be9d1-13a5-4b53-8202-0376c103961f","acronym":"SUNRAY-02","url":"https://clinicaltrials.gov/study/NCT06890598","created_at":"2025-06-07T14:38:17.196Z","updated_at":"2025-06-07T14:38:17.196Z","phase":"Phase 3","brief_title":"Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT06890598 - SUNRAY-02","lead_sponsor":"Eli Lilly and Company","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Imfinzi (durvalumab) • olomorasib (LY3537982)"],"overall_status":"Recruiting","enrollment":" Enrollment 700","initiation":"Initiation: 03/27/2025","start_date":" 03/27/2025","primary_txt":" Primary completion: 05/01/2029","primary_completion_date":" 05/01/2029","study_txt":" Completion: 02/01/2032","study_completion_date":" 02/01/2032","last_update_posted":"2025-06-05"},{"id":"17de40db-c7f4-4c4a-854e-574167dd0b13","acronym":"APEAK","url":"https://clinicaltrials.gov/study/NCT06947811","created_at":"2025-06-07T14:40:16.432Z","updated_at":"2025-06-07T14:40:16.432Z","phase":"Phase 1/2","brief_title":"A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations","source_id_and_acronym":"NCT06947811 - APEAK","lead_sponsor":"Sun Yat-sen University","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Ameile (aumolertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 71","initiation":"Initiation: 06/09/2025","start_date":" 06/09/2025","primary_txt":" Primary completion: 03/01/2027","primary_completion_date":" 03/01/2027","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2025-06-04"},{"id":"bc3bb6b8-1b3c-44bb-bd18-0601367497f6","acronym":"","url":"https://clinicaltrials.gov/study/NCT07004244","created_at":"2025-06-07T14:43:35.952Z","updated_at":"2025-06-07T14:43:35.952Z","phase":"Phase 1","brief_title":"Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies","source_id_and_acronym":"NCT07004244","lead_sponsor":"Sichuan University","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 05/26/2025","start_date":" 05/26/2025","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-06-04"},{"id":"a81aca55-51bd-4c9d-98b4-44d67b97640e","acronym":"KANDLELIT-012","url":"https://clinicaltrials.gov/study/NCT06997497","created_at":"2025-06-07T14:50:31.299Z","updated_at":"2025-06-07T14:50:31.299Z","phase":"Phase 3","brief_title":"A Clinical Study of MK-1084 With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)","source_id_and_acronym":"NCT06997497 - KANDLELIT-012","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • calderasib (MK-1084) • levoleucovorin calcium"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 477","initiation":"Initiation: 07/17/2025","start_date":" 07/17/2025","primary_txt":" Primary completion: 08/27/2029","primary_completion_date":" 08/27/2029","study_txt":" Completion: 06/29/2031","study_completion_date":" 06/29/2031","last_update_posted":"2025-05-30"}]